Interesting presentation although it doesn't include any results theirs still a few gems
- Checkvacc will only be going to cohort 6 by the looks of the updated dosing slide instead of the original 8
- Oncarlytics will only have 3 cohorts before expanding to a RP2D Expansion and will start at 10^7
- Also appears that this is the first time that Imugene have outlined some sort of commercial pathway in which they are trying to attract partners.
- Vaxinia Mono appears to be i the last cohort (presumably OBD) as there are no further cohorts planned on the slides
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
0.005(1.35%) |
Mkt cap ! $82.39M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.5¢ | 36.0¢ | $342.2K | 938.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 488 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 12566 | 2 |
View Market Depth
| Last trade - 16.10pm 18/07/2025 (20 minute delay) ? |
| IMU (ASX) Chart |